Tixagevimab/Cilgavimab Significantly Reduces SARS-CoV-2 Infections in Solid Organ Transplant Recipients

A recent study conducted at the Beth Israel Deaconess Medical Center has shed light on the effectiveness of tixagevimab/cilgavimab in preventing breakthrough SARS-CoV-2 infections in solid organ transplant (SOT) recipients. The research, which was published in the Transplantation Proceedings journal, demonstrates that the monoclonal antibodies can significantly reduce the rate of SARS-CoV-2 infections in this high-risk population.

Key Takeaways:

• The study included 323 patients, with 248 receiving tixagevimab/cilgavimab and 75 serving as controls.
• Tixagevimab/cilgavimab recipients had a significantly higher COVID-19 vaccination rate (99.6% vs 92.0%, P < 0.001).
• There were no differences in symptom frequency, illness severity, hospitalization rate, or treatment of SARS-CoV-2 infection between the two groups.
• The study found that tixagevimab/cilgavimab was associated with a significant decrease in the rate of SARS-CoV-2 infection among SOT recipients.

Statistics:

• The study cohort included 323 patients, with 248 receiving tixagevimab/cilgavimab and 75 serving as controls.
• COVID-19 vaccination rate was significantly higher among tixagevimab/cilgavimab recipients (99.6% vs 92.0%, P < 0.001).
• The log-rank test was used to compare the SARS-CoV-2-free survival curves between the two groups.
• The study found that tixagevimab/cilgavimab administration date and SARS-CoV-2 infection were significant predictors of SARS-CoV-2-free survival.

Sources:

• Tixagevimab-cilgavimab Decreases the Rate of Sars-cov-2 Infection Among Solid Organ Transplant Recipients. Transplantation Proceedings, 2023;55(8):1784-1792.
• Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA (www.elsevier.com).
• Beth Israel Deaconess Medical Center, 375 Longwood Ave, ROOM425, Boston, MA 02215, United States.